20.11.2014 Views

Is treating Blood pressure alone enough to protect your

Is treating Blood pressure alone enough to protect your

Is treating Blood pressure alone enough to protect your

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Caduet … Early Improvements in Arterial Wall<br />

Compliance<br />

AVALON-AWC AWC * study strongly<br />

suggests that a greater early<br />

vascular benefit can be<br />

obtained from simultaneous<br />

treatment with amlodipine and<br />

a<strong>to</strong>rvastatin, vs. either agent<br />

<strong>alone</strong>, in patients with<br />

hypertension and<br />

dyslipidemia.<br />

11.70%<br />

19.30%<br />

1.30%<br />

3.10%<br />

Placebo A<strong>to</strong>rvastatin Amlodipine Caduet 5/10<br />

Effect of treatment on small artery compliance (c2) At week 8,<br />

1- Cohn JN. AVALON-AWC: Arterial Wall Compliance in the A<strong>to</strong>rvastatin and Amlodipine in Patients With Elevated Lipids and Hypertension Trial. Am J<br />

Hypertens 2009; 22:137-44.<br />

Caduet … Reversal of LDL-induced Endothelial Dysfunction<br />

Endothelial dysfunction contributes <strong>to</strong> mechanisms of atherogenesis and its<br />

clinical manifestations, including coronary artery disease. 1<br />

Effect of Caduet ®1<br />

100%<br />

90%<br />

80%<br />

60%<br />

40%<br />

20%<br />

0%<br />

‐20%<br />

‐40%<br />

‐60%<br />

% increase in NO ¤<br />

% d ti i i ONOO º<br />

‐50%<br />

Caduet partially res<strong>to</strong>red the NO level of LDL*-induced dysfunctional<br />

endothelium. 1<br />

Effect of Caduet may be enhanced by antioxidant properties related <strong>to</strong> their<br />

intermolecular actions in the cell membrane and an increase in the<br />

expression and coupling of endothelial nitric oxide synthase. 1<br />

¤ NO: Nitric Oxide,<br />

º ONOO-: Cy<strong>to</strong><strong>to</strong>xic Peroxynitrite<br />

*LDL: Low-density Lipoprotein<br />

1- Mason RP. A rationale for combination therapy in risk fac<strong>to</strong>r management: a mechanistic perspective. The American Journal of<br />

Medicine. 2005; 118(12A): 54S-61S.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!